Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 10, Issue 8, 2008, Pages 652-660

  Schwarz, S L ^a   Gerich, J E ^b   Marcellari, A ^c   Jean louis, L ^c   Purkayastha, D ^c   Baron, Michelle A ^c  

^a Diabetes and Glandular Disease Clinic   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Efficacy; Initial combination therapy; Monotherapy

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; CARDIAC AGENT; GLIBENCLAMIDE; HEMOGLOBIN A1C; METFORMIN; NATEGLINIDE; PLACEBO;

AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; ASTHENIA; BRONCHITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; GERIATRIC PATIENT; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION;

EID: 47949127377     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00792.x     Document Type: Article

References (23)

1. Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: Results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2000; 23: 176-180.
2. Matyka K, Evans M, Lomas J, Cranston I, Macdonald I, Amiel SA. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997; 20: 135-141.
3. Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: Causes and strategies for prevention. Drugs Aging 2004; 21: 511-530.
4. Bristol-Myers Squibb Co. Glucophage ® (metformin hydrochloride tablets); Glucophage ® XR (metformin hydrochloride extended-release tablets). Princeton, Bristol-Myers Squibb Co., 2004.
5. GlaxoSmithKline. Avandia ® (rosiglitazone maleate tablets) Prescribing Information. Research Triangle Park, GlaxoSmithKline. 2001.
6. Takeda Pharmaceuticals America, Inc. Actos ® (pioglitazone hydrochloride tablets) Prescribing Information. Lincolnshire, Takeda Pharmaceuticals America, Inc. 2002.
7. Hollander PA, Schwartz SL, Gatlin MR et al. Importance of early insulin secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001; 24: 983-988.
8. Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 2002; 87: 4171-4176.
9. Saloranta C, Guitard C, Pecher E et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care 2002; 25: 2141-2146.
10. Del Prato S, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care 2003; 26: 2075-2080.
11. Fonseca VA, Kelley DE, Cefalu W et al. Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus. Metabolism 2004; 53: 1331-1335.
12. Ligueros-Saylan M, Khalilieh S, Lee J et al. Nateglinide has a low hypoglycemic potential in a missed-meal situation. Diabetologia 2000; 43 (Suppl. 1): A187.
13. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA. PRESERVE-β: Two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005; 28: 2093-2099.
14. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000; 23: 202-207.
15. Horton ES, Foley JE, Shen SG, Baron MA. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2004; 20: 883-889.
16. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3598-3604.
17. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002; 4: 201-208.
18. Rajagopalan R, Perez A, Ye Z, Khan M, Murray FT. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. Drugs Aging 2004; 21: 259-271.
19. Rajagopalan R, Xu Y, Abbadessa M. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: A post hoc analysis of four randomized trials. Am J Geriatr Pharmacother 2006; 4: 123-133.
20. Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21: 518-524.
21. Shorr RI, Franse LV, Resnick HE, Bari MD, Johnson KC, Pahor M. Glycemic control of older adults with type 2 diabetes: Findings from the Third National Health and Nutrition Examination Survey, 1988-1994. J Am Geriatr Soc 2000; 48: 264-267.
22. Meneilly GS, Cheung E, Tuokko H. Altered responses to hypoglycemia of healthy elderly people. J Clin Endocrinol Metab 1994; 78: 1341-1348.
23. Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994; 43: 403-410.